BB:BCART Biocartis Group NV

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions to improve clinical practice. The company offers oncology assays, such as Idylla Epidermal growth factor receptor (EGFR) Mutation Assay, an assay for the detection of 53 mutations in exons 18, 19, 20, and 21 of the EGFR gene; Idylla Serine/threonine-protein kinase B-raf (BRAF) Mutation Test to detect BRAF V600E, E2, D, K, R, and M mutations in formalin fixed paraffin embedded samples; and Idylla Kirsten rat sarcoma-2 virus oncogene (KRAS) Mutation Test, an in vitro diagnostic test for the detection of mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS oncogene. Its oncology assays also include Idylla Neuroblastoma RAS viral (v-ras) oncogene (NRAS)-BRAF-EGFR S492R Mutation Assay, an in vitro diagnostic test to detect mutations in codons 12, 13, 59, 61, 117, and 146 of the NRAS oncogene, as well as codon 600 of the BRAF oncogene and codon 492 of the EGFR gene; and Idylla ctBRAF Mutation Assay, an automated liquid biopsy assay for the detection of V600E/E2/D and V600K/R/M mutations in codon 600 of the BRAF gene. In addition, the company's oncology assays comprise Idylla ctKRAS Mutation Assay, an assay to detect mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS gene; Idylla NRAS-BRAF Mutation Test, an in vitro diagnostic test to detect NRAS mutations in codons 12, 13, 59, 61, 117 and 146 of the NRAS oncogene, as well as BRAF mutations in codon 600; Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay, a molecular assay to detect mutations in codons 12, 13, 59, 61, 117, 146 of the NRAS gene, as well as mutations in codon 600 of the BRAF gene and codon 492 of the EGFR gene. Further, it offers Idylla Respiratory (Influenza Virus (IFV)-Respiratory Syncytial Virus (RSV)) Panel, an infectious disease assay for the detection of various strains of IFV and RSV. Biocartis Group NV has a strategic partnership with ETPL. The company was founded in 2007 and is based in Mechelen, Belgium.

3.38 EUR
As of 01/14/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  04/27/2015
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   203,136,320 EUR
Current dividend yield:   0.00%
Sedol:      BWWYKX6

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy